Kamada to Announce Third Quarter and Nine-Months Ended September 30, 2024 Financial Results and Host Conference Call on November 13, 2024
Kamada (NASDAQ: KMDA) announced it will release its Q3 and nine-months financial results for the period ended September 30, 2024, before U.S. markets open on November 13, 2024. The company will host an investment community conference call at 8:30am Eastern Time on the same day. Shareholders can participate by dialing specific numbers for U.S., Israel, and International access. The call will also be available via webcast.
Kamada (NASDAQ: KMDA) ha annunciato che rilascerà i suoi risultati finanziari del terzo trimestre e dei nove mesi per il periodo concluso il 30 settembre 2024, prima dell'apertura dei mercati statunitensi il 13 novembre 2024. L'azienda ospiterà una conference call per la comunità degli investitori alle 8:30 ora orientale dello stesso giorno. Gli azionisti possono partecipare componendo numeri specifici per l'accesso da Stati Uniti, Israele e internazionale. La chiamata sarà disponibile anche tramite webcast.
Kamada (NASDAQ: KMDA) anunció que publicará sus resultados financieros del tercer trimestre y de los nueve meses para el período que finalizó el 30 de septiembre de 2024, antes de la apertura de los mercados de EE. UU. el 13 de noviembre de 2024. La compañía llevará a cabo una conferencia telefónica para la comunidad de inversores a las 8:30 a.m. hora del Este del mismo día. Los accionistas pueden participar marcando números específicos para el acceso desde EE. UU., Israel e internacional. La llamada también estará disponible a través de una transmisión por webcast.
Kamada (NASDAQ: KMDA)는 2024년 9월 30일로 종료된 3분기 및 9개월 재무 결과를 2024년 11월 13일 미국 시장이 열리기 전에 발표할 것이라고 발표했습니다. 회사는 같은 날 동부 표준시 기준 오전 8시 30분에 투자자 커뮤니티 컨퍼런스 콜을 진행합니다. 주주들은 미국, 이스라엘 및 국제 접근을 위해 특정 번호를 다이얼하여 참여할 수 있습니다. 이 통화는 웹캐스트를 통해서도 이용할 수 있습니다.
Kamada (NASDAQ: KMDA) a annoncé qu'elle publierait ses résultats financiers du troisième trimestre et des neuf mois pour la période se terminant le 30 septembre 2024, avant l'ouverture des marchés américains le 13 novembre 2024. La société organisera une conférence téléphonique pour la communauté des investisseurs à 8h30, heure de l'Est, le même jour. Les actionnaires peuvent participer en composant des numéros spécifiques pour un accès depuis les États-Unis, Israël et international. L'appel sera également disponible en webcast.
Kamada (NASDAQ: KMDA) gab bekannt, dass es seine Finanzergebnisse für das dritte Quartal und die ersten neun Monate für den Zeitraum bis zum 30. September 2024 vor der Eröffnung der US-Märkte am 13. November 2024 veröffentlicht. Das Unternehmen wird am selben Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz für die Investment-Community einrichten. Aktionäre können teilnehmen, indem sie spezielle Nummern für den Zugang aus den USA, Israel und international wählen. Die Konferenz wird auch über einen Webcast verfügbar sein.
- None.
- None.
REHOVOT, Israel and HOBOKEN, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, today announced that it will release financial results for the third quarter and nine-months ended September 30, 2024, prior to the open of the U.S. financial markets on Wednesday, November 13, 2024.
Kamada management will host an investment community conference call on Wednesday, November 13 at 8:30am Eastern Time to discuss these results and answer questions. Shareholders and other interested parties may participate in the call by dialing 1-877-407-0792 (from within the U.S.) or 1-809-406-247 (from Israel) or 1-201-689-8263 (International) using conference I.D. 13749715. The call will be webcast live on the internet at: https://viavid.webcasts.com/starthere.jsp?ei=1694075&tp_key=3a2494a103
About Kamada
Kamada Ltd. (the “Company”) is a global biopharmaceutical company with a portfolio of marketed products indicated for rare and serious conditions and a leader in the specialty plasma-derived field, focused on diseases of limited treatment alternatives. The Company is also advancing an innovative development pipeline targeting areas of significant unmet medical need. The Company’s strategy is focused on driving profitable growth from its significant commercial catalysts as well as its manufacturing and development expertise in the plasma-derived and biopharmaceutical fields. The Company’s commercial products portfolio includes six FDA approved plasma-derived biopharmaceutical products: KEDRAB®, CYTOGAM®, WINRHO SDF®, VARIZIG®, HEPAGAM B® and GLASSIA®, as well as KAMRAB®, KAMRHO (D)® and two types of equine-based anti-snake venom (ASV) products. The Company distributes its commercial products portfolio directly, and through strategic partners or third-party distributors in more than 30 countries, including the U.S., Canada, Israel, Russia, Argentina, Brazil, India, Australia and other countries in Latin America, Europe, the Middle East, and Asia. The Company leverages its expertise and presence in the Israeli market to distribute, for use in Israel, more than 25 pharmaceutical products that are supplied by international manufacturers. During recent years the Company added eleven biosimilar products to its Israeli distribution portfolio, which, subject to the European Medicines Agency (EMA) and the Israeli Ministry of Health approvals, are expected to be launched in Israel through 2028. The Company owns an FDA licensed plasma collection center in Beaumont, Texas, which currently specializes in the collection of Anti-Rabies and Anti-D hyper-immune plasma used in the manufacturing of the Company’s relevant products and recently opened a new plasma collection center in Houston, Texas in which it collects normal source plasma and specialty plasma. In addition to the Company’s commercial operation, it invests in research and development of new product candidates. The Company’s leading investigational product is an inhaled AAT for the treatment of AAT deficiency, for which it is continuing to progress the InnovAATe clinical trial, a randomized, double-blind, placebo-controlled, pivotal Phase 3 trial. FIMI Opportunity Funds, the leading private equity firm in Israel, is the Company’s controlling shareholder, beneficially owning approximately
CONTACTS:
Chaime Orlev
Chief Financial Officer
IR@kamada.com
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578
britchie@LifeSciAdvisors.com
FAQ
When will Kamada (KMDA) release its Q3 2024 financial results?
What time is Kamada's (KMDA) Q3 2024 earnings conference call?
How can investors join Kamada's (KMDA) Q3 2024 earnings call?
